Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702847 | 1.00 | PTGDR2 (0.34) | PTGDR2PTGDRTBXA2RL3MBTL1CYP2C9 | |
| SCHEMBL701281 | 0.93 | L3MBTL1 (0.39) | PTGDR2PTGDRTBXA2RL3MBTL1CYP2C9 | |
| SCHEMBL701282 | 0.93 | L3MBTL1 (0.39) | PTGDR2PTGDRTBXA2RL3MBTL1CYP2C9 | |
| SCHEMBL700247 | 0.93 | PTGDR2 (0.34) | PTGDR2PTGDRTBXA2RL3MBTL1CACNA1B | |
| SCHEMBL700249 | 0.93 | PTGDR2 (0.34) | PTGDR2PTGDRTBXA2RL3MBTL1CACNA1B | |
| SCHEMBL700546 | 0.92 | L3MBTL1 (0.36) | PTGDR2PTGDRTBXA2RL3MBTL1CYP2C9 | |
| SCHEMBL700547 | 0.92 | L3MBTL1 (0.36) | PTGDR2PTGDRTBXA2RL3MBTL1CYP2C9 | |
| SCHEMBL702053 | 0.92 | PTGDR2 (0.35) | PTGDR2PTGDRTBXA2RL3MBTL1CYP2C9 | |
| SCHEMBL702052 | 0.92 | PTGDR2 (0.35) | PTGDR2PTGDRTBXA2RL3MBTL1CYP2C9 | |
| SCHEMBL701379 | 0.91 | GCK (0.36) | PTGDR2PTGDRTBXA2RL3MBTL1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | claimed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | claimed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | claimed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | PTGDR2 15/4885PTGDR 11/4885TBXA2R 8/4885 |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | PTGDR2 15/4885PTGDR 11/4885TBXA2R 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.